Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15893MR)

This product GTTS-WQ15893MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15893MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11296MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ11081MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ15854MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ4771MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ11821MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ6183MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ6149MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ9172MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW